Single dose treatment with Tiberal of Giardia lamblia infection in children

Area of Science:

• Medical Research
• Parasitology
• Pediatrics

Background:

• Giardia lamblia is a common cause of parasitic infection in children.
• Metronidazole is a standard treatment, but new derivatives are being explored for efficacy and safety.
• Accurate diagnosis of giardiasis is crucial for effective treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of a new metronidazole derivative, Tiberal (Ro-07-0207), in pediatric patients with Giardia lamblia infection.
• To compare diagnostic methods for Giardia lamblia, focusing on the reliability of the mucosal imprint technique.

Main Methods:

• A study involving 22 children diagnosed with Giardia lamblia infection.
• Two dosage regimens of Tiberal were administered: 1g twice daily for one day, or a single dose of 50 mg/kg.
• Parasitological cure was assessed, and side effects were monitored.
• Diagnostic methods including stool examination, duodenal juice analysis, jejunal biopsy, and mucosal imprints were compared.

Main Results:

• All 22 children achieved parasitological cure after treatment with Tiberal.
• Significant side effects were observed only in the group receiving the higher dosage regimen (50 mg/kg).
• The mucosal imprint method was confirmed to be more reliable for detecting Giardia lamblia than stool, duodenal juice, or jejunal biopsy examinations.

Conclusions:

• Tiberal is an effective treatment for Giardia lamblia infection in children.
• Dosage optimization is necessary to minimize side effects associated with Tiberal.
• The mucosal imprint technique offers a more reliable diagnostic approach for giardiasis.